Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - imatinib mesilate - film-coated tablet - 100 milligram(s) - protein kinase inhibitors; imatinib

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - imatinib mesilate - film-coated tablet - 400 milligram(s) - protein kinase inhibitors; imatinib

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - clopidogrel besilate, quantity: 111.86 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: mannitol; microcrystalline cellulose; colloidal anhydrous silica; stearic acid; hypromellose; titanium dioxide; iron oxide red - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.,acute coronary syndrome,clopidogrel is indicated in combination with aspirin for patients with,-unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-termatherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent).,- st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in thispopulation, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; iron oxide yellow; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; macrogol 4000 - exforge is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg); valsartan, quantity: 320 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; iron oxide yellow; crospovidone; sodium starch glycollate; colloidal anhydrous silica; hypromellose; purified talc; macrogol 4000; iron oxide red - exforge is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - amlodipine besilate, quantity: 6.944 mg (equivalent: amlodipine, qty 5 mg); olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; pregelatinised maize starch; microcrystalline cellulose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - sevikar is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - olmesartan medoxomil, quantity: 20 mg; amlodipine besilate, quantity: 13.888 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; purified talc; iron oxide red; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - sevikar is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; crospovidone; titanium dioxide; hypromellose; purified talc; macrogol 4000; iron oxide red; iron oxide yellow - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg; amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; hypromellose; iron oxide yellow; purified talc; macrogol 4000; titanium dioxide - amlodipine/valsartan novartis is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - saquinavir mesilate, quantity: 571.5 mg (equivalent: saquinavir, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; triacetin; croscarmellose sodium; titanium dioxide; hypromellose; purified talc; iron oxide red; lactose monohydrate; iron oxide yellow; magnesium stearate - invirase (saquinavir) is indicated for the treatment of hiv/aids in adults and children 12 years of age or older. clinical studies indicate that saquinavir should only be used in combination with ritonavir and other anti-retroviral therapies (see clinical trials). this indication is based on changes in surrogate markers. at present there are no results from controlled clinical trials evaluating the effect of regimens containing saquinavir on hiv disease progression or survival (see clinical trials).